New study finds triple-negative breast cancer tumors with an increase in immune cells have lower risk of recurrence after surgery

ROCHESTER, Minn. — A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy. The study was published today in the Journal of American Medical Association (JAMA). TNBC is a breast cancer subtype that does not respond to drugs that target the estrogen receptor or…
Source: Mayo Clinic Research News - Category: Research Source Type: news